^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

392P - A phase II study of SAF-189s in patients with advanced ROS1 fusion-positive non-small cell lung cancer

Published date:
11/28/2022
Excerpt:
This multicenter, single-arm, open-label, Ph2 study enrolled Chinese patients with advanced ROS1+ NSCLC….IRC-confirmed ORR in ROS1i-naïve pts were 94.1% and 80.4% and DCR were 94.1% and 96.4% in pts in Ph2a and Ph2b respectively. Notably, confirmed ORRs and DCRs were similar in pts with and without brain metastasis (Table). Median PFS was 16.5 mo in Ph 2a and not reached in Ph 2b. In crizotinib-pretreated pts in Ph2a, confirmed ORR was 40% and median PFS was 5.5 mo....These findings demonstrate the promising clinical activity and a tolerable toxicity profile of SAF-189s in pts with advanced ROS1+ NSCLC...
Trial ID: